TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 38, 2016, Pages E5655-E5664

  Zhao, Xiaobei ^a   Chen, Xu Qiao ^a   Han, Eugene ^a   Hu, Yue ^a   Paik, Paul ^a   Ding, Zhiyong ^b   Overman, Julia ^c   Lau, Alice L ^c   Shahmoradian, Sarah H ^d   Chiu, Wah ^d   Thompson, Leslie M ^c   Wu, Chengbiao ^a   Mobley, William C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

BACHD mouse model; BDNF transport; Huntington's disease; Striatal atrophy; TRiC chaperonin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CHAPERONIN CONTAINING TCP1; HUNTINGTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN CELL; BRAIN CELL CULTURE; COCULTURE; CONTROLLED STUDY; CORPUS STRIATUM; EMBRYO; HUNTINGTON CHOREA; LYSOSOME; MICROFLUIDIC ANALYSIS; MOUSE; NERVE FIBER TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECRETION; PROTEIN SYNTHESIS; RETROGRADE NERVE FIBER TRANSPORT; SYNAPSE; ANIMAL; ATROPHY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; LAB ON A CHIP; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; SPINOCEREBELLAR DEGENERATION;

ANIMALS; ATROPHY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHAPERONIN CONTAINING TCP-1; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; LAB-ON-A-CHIP DEVICES; MICE; MUTATION; NEURONS; RECEPTOR, TRKB; SPINOCEREBELLAR DEGENERATIONS;

EID: 84988597053     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1603020113     Document Type: Article

References (68)

1. Ross CA, Tabrizi SJ (2011) Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83-98.
2. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369-384.
3. Estrada Sánchez AM, Mejía-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39(3):265-276.
4. Bennett EJ, et al. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448(7154):704-708.
5. Browne SE (2008) Mitochondria and Huntington's disease pathogenesis: Insight from genetic and chemical models. Ann N Y Acad Sci 1147:358-382.
6. Wang N, et al. (2014) Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat Med 20(5):536-541.
7. Cattaneo E, et al. (2001) Loss of normal huntingtin function: New developments in Huntington's disease research. Trends Neurosci 24(3):182-188.
8. Zuccato C, et al. (2005) Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res 52(2):133-139.
9. Zuccato C, et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293(5529):493-498.
10. Lu B, Nagappan G, Lu Y (2014) BDNF and synaptic plasticity, cognitive function, and dysfunction. Handbook Exp Pharmacol 220:223-250.
11. Altar CA, et al. (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389(6653):856-860.
12. Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 81(5-6):294-330.
13. Ginés S, et al. (2006) Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci 23(3):649-658.
14. Strand AD, et al. (2007) Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27(43):11758-11768.
15. Canals JM, et al. (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 24(35):7727-7739.
16. Chagoyen M, Carrascosa JL, Pazos F, Valpuesta JM (2014) Molecular determinants of the ATP hydrolysis asymmetry of the CCT chaperonin complex. Proteins 82(5):703-707.
17. Frydman J (2001) Folding of newly translated proteins in vivo: The role of molecular chaperones. Annu Rev Biochem 70:603-647.
18. Dunn AY, Melville MW, Frydman J (2001) Review: Cellular substrates of the eukaryotic chaperonin TRiC/CCT. J Struct Biol 135(2):176-184.
19. Spiess C, Meyer AS, Reissmann S, Frydman J (2004) Mechanism of the eukaryotic chaperonin: Protein folding in the chamber of secrets. Trends Cell Biol 14(11):598-604.
20. Tam S, Geller R, Spiess C, Frydman J (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8(10):1155-1162.
21. Kabir MA, et al. (2011) Functional subunits of eukaryotic chaperonin CCT/TRiC in protein folding. J Amino Acids 2011:843206.
22. Kitamura A, et al. (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 8(10):1163-1170.
23. Jana NR, Tanaka M, Wang Gh, Nukina N (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 9(13):2009-2018.
24. Gunawardena S, et al. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40(1):25-40.
25. Cong Y, et al. (2010) 4.0-A resolution cryo-EM structure of the mammalian chaperonin TRiC/CCT reveals its unique subunit arrangement. Proc Natl Acad Sci USA 107(11):4967-4972.
26. Sontag EM, et al. (2013) Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci USA 110(8):3077-3082.
27. Darrow MC, et al. (2015) Structural mechanisms of mutant huntingtin aggregation suppression by the synthetic chaperonin-like CCT5 complex Explained by cryoelectron tomography. J Biol Chem 290(28):17451-17461.
28. Gray M, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182-6195.
29. Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 30(44):14708-14718.
30. Aylward EH, et al. (2004) Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63(1):66-72.
31. Baquet ZC, Gorski JA, Jones KR (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24(17):4250-4258.
32. Li Y, et al. (2012) Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development. Proc Natl Acad Sci USA 109(38):15491-15496.
33. Gorski JA, Zeiler SR, Tamowski S, Jones KR (2003) Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J Neurosci 23(17):6856-6865.
34. Swift DL, et al. (2012) The effect of exercise training modality on serum brain derived neurotrophic factor levels in individuals with type 2 diabetes. PLoS One 7(8):e42785.
35. Kolbeck R, Bartke I, Eberle W, Barde YA (1999) Brain-derived neurotrophic factor levels in the nervous system of wild-type and neurotrophin gene mutant mice. J Neurochem 72(5):1930-1938.
36. Matsumoto T, et al. (2008) Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 11(2):131-133.
37. Dieni S, et al. (2012) BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. J Cell Biol 196(6):775-788.
38. Zhao X, et al. (2014) Real-time imaging of axonal transport of quantum dot-labeled BDNF in primary neurons. J Vis Exp (91):51899.
39. Weissmiller AM, et al. (2015) A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: Evidence for a role for APP. PLoS One 10(2):e0118379.
40. Gu X, et al. (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64(6):828-840.
41. von Bartheld CS (2004) Axonal transport and neuronal transcytosis of trophic factors, tracers, and pathogens. J Neurobiol 58(2):295-314.
42. Cazorla M, et al. (2011) Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 121(5):1846-1857.
43. Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14(1):7-23.
44. Liot G, et al. (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci 33(15):6298-6309.
45. Caviston JP, Ross JL, Antony SM, Tokito M, Holzbaur EL (2007) Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc Natl Acad Sci USA 104(24):10045-10050.
46. McGuire JR, Rong J, Li SH, Li XJ (2006) Interaction of Huntingtin-associated protein-1 with kinesin light chain: Implications in intracellular trafficking in neurons. J Biol Chem 281(6):3552-3559.
47. Caviston JP, Holzbaur EL (2009) Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 19(4):147-155.
48. Caviston JP, Zajac AL, Tokito M, Holzbaur EL (2011) Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes. Mol Biol Cell 22(4):478-492.
49. Apostol BL, et al. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 100(10):5950-5955.
50. Wheeler VC, et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9(4):503-513.
51. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90(3):905-981.
52. Gu X, et al. (2007) Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener 2:8.
53. Gu X, et al. (2005) Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46(3):433-444.
54. Thomas EA, et al. (2011) In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet 20(6):1049-1060.
55. Estrada-Sánchez AM, et al. (2015) Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease. J Neurosci 35(10):4440-4451.
56. Gauthier LR, et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127-138.
57. Shirasaki DI, et al. (2012) Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 75(1):41-57.
58. Teuling E, et al. (2011) Modifiers of mutant huntingtin aggregation: Functional conservation of C. elegans-modifiers of polyglutamine aggregation. PLoS Curr 3:RRN1255.
59. Kordasiewicz HB, et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74(6):1031-1044.
60. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101(1):57-66.
61. Martín-Aparicio E, et al. (2001) Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 21(22):8772-8781.
62. McClellan AJ, Tam S, Kaganovich D, Frydman J (2005) Protein quality control: Chaperones culling corrupt conformations. Nat Cell Biol 7(8):736-741.
63. Kegel KB, et al. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 20(19):7268-7278.
64. Gascón S, Paez-Gomez JA, Díaz-Guerra M, Scheiffele P, Scholl FG (2008) Dual-promoter lentiviral vectors for constitutive and regulated gene expression in neurons. J Neurosci Methods 168(1):104-112.
65. Tam S, et al. (2009) The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 16(12):1279-1285.
66. Sontag EM, et al. (2012) Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci 32(32):11109-11119.
67. Wu C, Lai CF, Mobley WC (2001) Nerve growth factor activates persistent Rap1 signaling in endosomes. J Neurosci 21(15):5406-5416.
68. Scherzinger E, et al. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90(3):549-558.